Skip to main content

Table 5 Anti-cancer drug resistance-associated lncRNAs in CML

From: Long non-coding RNAs in hematological malignancies: translating basic techniques into diagnostic and therapeutic strategies

lncRNA

Sample source

Functional involvement and mechanism of action lncRNAs in drug resistance

Approaches for lncRNAs characterization in drug resistance

References

Cell proliferation/cytotoxicity, cell viability assay

Manipulation approaches for lncRNAs

Mechanism characterization approach

UCA1

Imatinib-resistant cell lines

Modulates imatinib resistance by acting as a ceRNA against miR-16

CCK-8 assay

siRNAs

RIP assay, Dual-luciferase reporter assay

[123]

SNHG5

Patient samples, imatinib-resistant cell lines

Promotes imatinib resistance through acting as ceRNA against miR-205-5p

MTT assay

siRNAs

RIP assay, Luciferase reporter assay

[125]

HOTAIR

Multidrug-resistant patient samples, imatinib-resistant cell lines

Modulates MDR to imatinib resistance through activating PI3K/Akt-dependent pathway

MTT assay, Annexin V/propidium iodide (PI) staining assay

siRNAs

–

[126]

MEG3

Patient samples, imatinib-resistant cell lines

Inhibits imatinib resistance by suppressing miR-21

CCK-8 assay, Annexin V-FITC/PI Apoptosis Detection Kit

Overexpression

Luciferase reporter assay

[127]